Janssen's Incivo to outshine Merck's Victrelis after fast-tracked NICE yes
This article was originally published in Scrip
Janssen-Cilag's hepatitis C treatment Incivo (telaprevir) looks set to join rival drug Merck & Co's Victrelis (boceprevir) as an NHS treatment option in England and Wales after NICE, the health technology appraisal institute, fast-tracked final draft guidance recommending the drug, just one week after it did the same for fellow protease inhibitor Victrelis. However, analysts expect that sales of Incivo will eventually outstrip sales of Victrelis in the UK, as they have in the US.
You may also be interested in...
Denmark is moving to a QALY based evaluation system for hospital drugs. Despite a more complex process, the change could still mean quicker market access, says the pharmaceutical industry.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.